P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
L. Nastoupil,
F. Morschhauser,
C. W. Scholz,
M. Bishton,
S.-S. Yoon,
P. Giri,
M. C. Wei,
A. Knapp,
C.-C. Li,
A. Bottos,
H. Li,
E. Purev,
N. L. Bartlett
Affiliations
L. Nastoupil
1 Emory University, Atlanta, GA, United States of America
F. Morschhauser
2 University of Lille, CHU Lille, Lille, France
C. W. Scholz
3 Vivantes Klinikum am Urban, Berlin, Germany
M. Bishton
4 Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
S.-S. Yoon
5 Seoul National University Hospital, Seoul, South Korea
P. Giri
6 Royal Adelaide Hospital, Adelaide, Australia
M. C. Wei
7 Genentech, Inc., South San Francisco, CA, United States of America
A. Knapp
8 F. Hoffmann-La Roche Ltd, Basel, Switzerland
C.-C. Li
7 Genentech, Inc., South San Francisco, CA, United States of America
A. Bottos
8 F. Hoffmann-La Roche Ltd, Basel, Switzerland
H. Li
9 Hoffmann-La Roche Ltd, Mississauga, ON, Canada
E. Purev
7 Genentech, Inc., South San Francisco, CA, United States of America
N. L. Bartlett
10 Washington University School of Medicine, St. Louis, United States of America
